Urgent Ophthalmology Assessment and Deprescribing Plan
This patient requires immediate ophthalmology evaluation within 24 hours and urgent stroke workup at a certified stroke center, with concurrent initiation of a systematic deprescribing plan for the multiple serotonergic medications that pose significant risk for both serotonin syndrome and vision-threatening complications.
Immediate Actions Required
1. Emergency Ophthalmology Referral
Send the patient immediately to an ophthalmologist or emergency department affiliated with a stroke center 1, 2. Progressive vision loss in the context of multiple psychotropic medications requires:
- Same-day comprehensive eye examination including:
- Visual acuity testing (Snellen chart)
- Intraocular pressure measurement
- Gonioscopy to assess anterior chamber angles
- Dilated fundus examination to evaluate for retinal artery occlusion or optic neuropathy
- Color discrimination testing (Ishihara)
The combination of fluoxetine with vortioxetine creates a particularly concerning scenario, as SSRIs are associated with angle-closure glaucoma, mydriasis, and optic neuropathy 3, 4, 5. Fluoxetine specifically has been linked to vision disorders including blurred vision and visual impairment 3.
2. Urgent Stroke Evaluation
Contact the nearest certified stroke center immediately 1. Progressive vision loss may represent retinal arterial ischemia, which carries a maximum stroke risk within the first few days 1, 2. The patient needs:
- Brain MRI with vascular imaging
- Carotid evaluation
- Cardiac workup
- Immediate antiplatelet therapy if vascular etiology confirmed
Critical Medication Safety Issue: Serotonin Syndrome Risk
This patient is on a dangerous combination of THREE serotonergic agents (fluoxetine, vortioxetine, trazodone) plus sedative-hypnotics (temazepam, hydroxyzine), creating substantial risk for serotonin syndrome 6.
Signs to Monitor for Serotonin Syndrome:
- Mental status changes (confusion, agitation, anxiety)
- Neuromuscular hyperactivity (tremors, clonus, hyperreflexia, muscle rigidity)
- Autonomic hyperactivity (hypertension, tachycardia, diaphoresis, shivering)
- Symptoms can arise within 24-48 hours after combining medications 6
Advanced symptoms include fever, seizures, arrhythmias, and unconsciousness leading to fatalities 6. Treatment requires hospitalization with discontinuation of all serotonergic agents 6.
Deprescribing Algorithm
Phase 1: Immediate (Within 24-48 Hours)
Discontinue trazodone immediately - This is the easiest medication to remove as it provides the least unique benefit in this regimen and contributes to serotonin syndrome risk. Trazodone's sedative effects are redundant with temazepam and hydroxyzine.
Phase 2: Week 1-2
Taper and discontinue temazepam over 7-14 days to avoid benzodiazepine withdrawal 7. Reduce by 25% every 3-4 days. The patient has hydroxyzine for anxiety/sleep support during this transition.
Phase 3: Week 2-4
Choose ONE primary antidepressant and discontinue the other:
Option A (Preferred): Continue vortioxetine, discontinue fluoxetine
- Vortioxetine has demonstrated efficacy for depression with cognitive benefits 8
- Fluoxetine has a very long half-life (4-6 days for fluoxetine, 4-16 days for active metabolite norfluoxetine) 6
- Simply stop fluoxetine - no taper needed due to long half-life 6
- Wait 5-6 weeks after stopping fluoxetine before optimizing vortioxetine dose to allow complete washout and avoid serotonin syndrome
Option B: Continue fluoxetine, discontinue vortioxetine
- If fluoxetine has been effective historically
- Taper vortioxetine over 1-2 weeks (reduce by 50% for one week, then discontinue)
- Fluoxetine 20mg is an appropriate maintenance dose 9
Phase 4: Ongoing
Reassess hydroxyzine necessity after 4-6 weeks. If anxiety/sleep have improved with simplified regimen, consider tapering hydroxyzine over 1-2 weeks.
Vision-Specific Medication Considerations
Fluoxetine poses specific ophthalmologic risks 3, 4, 5:
- Associated with angle-closure glaucoma (especially in predisposed eyes)
- Linked to optic neuropathy in case reports 4
- Can cause mydriasis, blurred vision, and visual impairment 3, 5
- SSRI-associated optic neuropathy may improve with drug cessation 4
If angle-closure glaucoma is diagnosed, fluoxetine should be permanently discontinued 5, 10. Vortioxetine would be the safer alternative, though all serotonergic agents carry some mydriatic risk 5.
Monitoring Plan
During Deprescribing:
- Weekly check-ins for first month (phone or in-person)
- Monitor for: worsening depression, anxiety, insomnia, withdrawal symptoms
- Watch for SSRI discontinuation syndrome (unlikely with fluoxetine due to long half-life, but possible with vortioxetine): dizziness, fatigue, headaches, nausea, sensory disturbances 6
Vision Monitoring:
- Immediate ophthalmology follow-up after initial evaluation
- Monthly visual acuity and color discrimination testing if continuing any serotonergic medication 11
- Instruct patient to report immediately: any vision changes, eye pain, halos around lights, or headaches
Common Pitfalls to Avoid
Do not attempt to treat all symptoms with medications - This patient's polypharmacy likely resulted from treating medication side effects with additional medications 7
Do not abruptly stop multiple medications simultaneously - This creates confusion about which medication caused which symptom and increases withdrawal risk
Do not underestimate fluoxetine's long half-life - Drug interactions can persist for 5-6 weeks after discontinuation 6
Do not dismiss vision complaints as "functional" - While functional vision disorders exist 12, this patient has objective risk factors requiring thorough evaluation
Do not delay ophthalmology referral - Vision loss with vascular etiology has maximum stroke risk in first few days 1, 2